Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 786Lung Neoplasms 347Small Cell Lung Carcinoma 146Adenocarcinoma of Lung 71Neoplasms 45Neoplasm Metastasis 35Adenocarcinoma, Bronchiolo-Alveolar 30Colorectal Neoplasms 26Carcinoma 25Ovarian Neoplasms 24Lung Diseases 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Breast Neoplasms 17Mesothelioma 16Thoracic Neoplasms 15Respiratory Tract Neoplasms 15Mesothelioma, Malignant 15Pancreatic Neoplasms 14NSCLC 13Endometrial Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Carcinoma, Bronchogenic 12Adenocarcinoma 12Melanoma 11Triple Negative Breast Neoplasms 10Stomach Neoplasms 10Brain Neoplasms 10Respiratory Tract Diseases 9Head and Neck Neoplasms 9Carcinoma, Squamous Cell 9

Interventions

pembrolizumab 1Radiotherapy 1Paclitaxel 1Erlotinib Hydrochloride 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Clear Cell × Carboplatin × Thoracic × Clear all
NCT00563784 2019-11-20

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 11 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Adenocarcinoma, Clear Cell, Carcinoma, Giant Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡